- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Patent holdings for IPC class A61P 5/50
Total number of patents in this class: 626
10-year publication summary
|
23
|
23
|
27
|
37
|
35
|
37
|
32
|
33
|
34
|
26
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2704 |
13 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
12 |
| Tsinghua University | 5973 |
8 |
| Sirtris Pharmaceuticals, Inc. | 33 |
8 |
| Boehringer Ingelheim Vetmedica GmbH | 1277 |
7 |
| President and Fellows of Harvard College | 6009 |
7 |
| Novo Nordisk A/S | 2272 |
7 |
| Sanofi | 4101 |
7 |
| Janssen Pharmaceutica N.V. | 3367 |
6 |
| Sanofi-Aventis Deutschland GmbH | 2613 |
5 |
| Beijing Protgen Ltd. | 22 |
5 |
| Cornell University | 3341 |
5 |
| Novartis AG | 10707 |
4 |
| Amgen Inc. | 4122 |
4 |
| Vertex Pharmaceuticals Incorporated | 1627 |
4 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 708 |
4 |
| The George Institute for Global Health | 29 |
4 |
| Mankind Pharma Limited. | 75 |
4 |
| Sanovel Ilac Sanayi ve Ticaret A.S. | 287 |
4 |
| Sichuan Haisco Pharmaceutical Co., Ltd. | 151 |
4 |
| Other owners | 504 |